epiPANCANCER- a Novel Blood Test for Accurate Early Detection of Cancer from 33 Different Originas Using a BCD-next Generation Method


It is widely established by now that tumor DNA is shed into the body and could be found in the plasma portion of whole blood even before the onset of clinical symptoms (Warton & Samimi, 2015). Isolating plasma from blood is a simple procedure that could be performed by any clinical lab in almost any hospital or nurse/doctor clinic. The main challenge is how to tell apart tumor DNA from all other normal DNA that finds itself in plasma. And moreover, how do we know if we detect cancer whether it is a liver cancer or some other cancer. It is like finding a needle in a haystack. Although screening for sequence mutations has held high promise, it appears now that it is not a highly effective way for detecting tumor DNA in blood.


However, there is a unique and novel way to detect few molecules of cancer DNA on the background of normal DNA, it is not by examining the genetic sequence but rather by examining the “epigenetic” profile of DNA. Research pioneered by Moshe Szyf, a professor at McGill University and a fellow of the Royal Society of Canada has taken almost three decades to establish the unique epigenetic characteristics of cancer cells and their DNA. Our team has identified a set of regions that are
methylated in almost all cancers and are not methylated in any normal tissue examined and are therefore used to detect cancer in our assay.

Disclaimer: This test was developed and its performance characteristics determined by HKG epiTherapeutics Limited. It has not been cleared or approved by the US Food and Drug Administration. HKG epiTherapeutics Limited is committed to maintain the accuracy, security nd confidentiality of your personal information. epiPancancer is not a replacement for traditional biopsy methods but rather an additional tool in the diagnosis and management of cancer.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top